ASCO® 2025 Highlights: Presenter Vignette – Christophe Le Tourneau
Christophe Le Tourneau
MD, PhD
Institut Curie
6016
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
